The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

How can pharmaceutical firms shore up their sustainability credentials at a time when the entire research landscape is turning on its head? A recent webinar from supply chain leaders World Courier and ...

The InPen app can take a blood sugar reading from the Simplera CGM or blood glucose meter and calculate a premeal dose or correction, if necessary, based on the glucose reading, active insulin, and ...

Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

Injectable Drug Delivery MarketThe global injectable drug delivery market is estimated to be valued at USD 49.44 billion in 2024, with strong growth expectations due to advancements in healthcare, ...

Novo Nordisk lowered the list price on various insulin products, including pre-filled insulin pens and vials. The company suggested that this would mean patients would pay $25-35 for their insulin.

Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies.